A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial—Pembrolizumab Low dose in Addition to NACT in TNBC)

A. Arora, H. Bhaskarane, Ghazal Tansir, Sameer Bakhshi, A. Gogia, A. Kumar, R. Jain, Kaushal Kalra, Divvay Vishvam, S. Mathur, Ruchi Rathore, S.A. Shamim, Ekta Dhamija, Krithika Rangarajan, P. Tanwar, C.P. Prasad, S. Kumar, I. Gupta, Kalaivani Mani, A.D. Upadhyay, M.K. Divakar, P. Vasudeva, N. Verma, S. Agstam, S. Vuthaluru, R. Parshad, VK Bansal, Anita Dhar, A. Krishna, Pratyush Ranjan, Suhani Suhani, Om Prakash, Kamal Kataria, B. Kumar, A. Mishra, J. Sharma, Babul Bansal, J. Saikia, Suman Bhasker, K.P. Haresh, S. Gupta, S.K. Saini, S. Mallick, A. Batra